Feature Report: Triple Digit Revenue Growth. Revenue Now Exceeds Their Market Cap with Net Profits, Expanding and Impressive Client Base Making This One Looks Like a Big Near Term Winner!
The company advancing the PHILUX Global Funds, PHI Group, Inc. (OTCPNK: PHIL) announced earlier this month that an agreement has been reached between Vietnam-based Ngoc Thien Phu Rice Export Import JSC (NTP) and PHI Group, Inc. to participate in PHILUX Global Food Fund (“PGFF”). According to the agreement, NTP will contribute a mutually agreed amount of capital for the setup and initial operating budget of the PGFF and hold 49% ownership of the general partners’ portion of this fund. PGFF will focus on food and food-related agricultural investment opportunities in Vietnam and other countries as well.
With more than 20 years of experience in the field of agricultural production, NTP has successfully built its ecosystem from individual farmers and agricultural cooperatives, to processing factories and trading companies in the Mekong Delta and Cambodia. This ecosystem has been operated systematically to properly manage paddy rice inputs and ensure the high quality of rice products.
NTP has engaged Swiss-based Buhler Group to build the first-ever state-of-the-art European-standard factory in Vietnam, also the biggest one in the Southeast Asia region, for processing various high quality clean rice products which are highly sought after in many countries.
Healthy living property developer, Alset EHome International Inc. (NASDAQ: AEI) released its FYE 2021 financials and it seems the company is doing well. The Group’s revenue rose 21.9% to approximately $19.8 million in FY2021 from $16.2 million in FY2020 due primarily to an increase in revenue from its biohealth business and rental income under its real estate business. The Group’s cash has more than doubled from approximately $25.0 million as of December 31, 2020, to $56.1 million as of December 31, 2021. In addition, the Group’s real estate assets have increased 97.6% to approximately $40.5 million as of December 31, 2021, from $20.5 million as of December 31, 2020.
Furthermore, the Group’s net assets have increased 173.8% to approximately $170.3 million as of December 31, 2021, from $98.0 million as of December 31, 2020, due mainly to increases in cash, real estate assets and investments in securities.
Company founder, Heng Fai Chan bought 11.96m shares over the last 12 months at an average price of $.77. Specifically, he spent $8.26M in this year alone buying up company shares. The purchases over the past year bring Chan’s overall holding to 38% of the company, many of the shares purchased at prices higher than the current market price. It is worthy to note that insiders own 46% of the company’s outstanding shares and there have been no recent insider sales.
The late-stage biotechnology company CytoDyn Inc. (OTCQB: CYDY) is developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, has announced the publication of a peer-reviewed research paper entitled “Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species” in the open-access journal PLOS Pathogens. The study followed five HIV+ human participants who, after successfully transitioning to once weekly subcutaneous leronlimab, halted their previous daily oral antiretroviral therapy regimens.
These five participants came from an extension study, consisting of patients who were virologically suppressed in a prior study of leronlimab. Of the ten patients enrolled in the extension study, four individuals experienced viral rebound and stopped leronlimab monotherapy, and one individual withdrew, leaving five long-term participants. All five long-term participants successfully maintained HIV suppression via leronlimab monotherapy for over seven years, with no evidence of viral escape.
To monitor the anatomical penetrance of leronlimab, rhesus macaques acutely infected with simian human immunodeficiency virus (SHIV) were treated with high intravenous doses of leronlimab for 12 weeks. Leronlimab treatment reduced SHIV viral loads by 10,000-fold and leronlimab was found within all anatomical compartments analyzed, including mucosal and lymphatic tissues, sites of early viral replication after transmission and latency, respectively.
Argentum 47, Inc. (OTCPNK: ARGQ) has announced that management has fully executed a legally binding letter of intent to acquire UK based company, The Data Source Limited (TDS). Management has been in negotiations with several parties since late 2021 to successfully complete a merger or acquisition. TDS is a data driven B2B and B2C solutions provider utilizing artificial intelligence with lead generation, automation, and analytics. TDS provides its clients with world class data with the aim of becoming a one-stop-shop for all things data.
Reuters, Vodafone, Revolut, Honda and American Express are just a few of the companies they have worked with. The next stage of development for TDS is within North America, where they are already making inroads into the real estate and capital markets sectors, offering services including business intelligence and research, demographic, market data and public data. TDS is also examining several complimentary acquisitions in Europe and in the United States and sees the potential acquisitions as a defined path for the combined companies in the years to come; hence, TDS is poised to increase its organic revenue substantially in the coming 12 months.
Feature Report: Triple Digit Revenue Growth. Revenue Now Exceeds Their Market Cap with Net Profits, Expanding and Impressive Client Base Making This One Looks Like a Big Near Term Winner!
The Traders News Group
Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Editor@TradersNewsSource.com
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have not been compensated for the mention of any of the publicly traded companies mentioned in this report. We do not hold any equity positions in any of the publicly traded companies mentioned in this report. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.
